Navigating by the Stars To Achieve a Brighter Future for Hometown Scientists
In 2013, to avoid monitoring by his manager, a truck driver at a New Jersey engineering firm purchased an illegal $50 GPS jammer that plugged into his vehicle's cigarette lighter. The device inadvertently also jammed the satellite system navigation capabilities of the entire Newark airport every time he drove by. The signals emanating from the vehicle were blocking the reception of GPS frequencies used by the air traffic control system, and planes were unable to safely land or take off, forcing the airport to close.
'People don't realize how vulnerable GPS is,' said Dr. Joshua Morales, owner and founder of StarNav, a startup tech company that provides hardware and software solutions enabling safe, reliable positioning and timing. 'StarNav's products convert terrestrial and low-Earth orbit satellite signals into reliable positioning and timing information, working even when GPS fails. Because GPS is used in critical U.S. infrastructure, such as time keeping, currency, communication, navigation, and energy, having a secondary way for keeping the country synchronized is an imperative.'
Navigational guidance by the stars is an ancient concept, but Morales and his team are innovating navigation for the future, and this work-with-what-you-have ethos has shaped much of Morales' journey. As part of this he is determined to keep his company in the Inland Empire area of Southern California, in order to create a profitable career hub for brilliant scientific minds who graduate from the areas many universities, rather than feeding into the intellectual exodus to the Silicon Valley that Inland Empire scientists currently face. StarNav began at one such local institution, the University of California, Riverside (UCR) as part of their Entrepreneurship Center (EPIC) which specializes in providing training, mentorship and access to capital to innovative, technology intensive businesses.
Over the past two years, U.S. Bank provided corporate contributions totaling $95,000 in support of UCR's Zero-to-Entrepreneur program, which is part of the SoCal OASIS™ regional economic development strategy focused on sustainability, innovation, social inclusion and workforce development in Inland Southern California and home to StarNav's early beginnings.
Morales earned his Ph.D. from UC Irvine in 2020. After completing his doctorate, he returned to Riverside, which is where attended UCR for his B.S. in Electrical Engineering. He has been a part of the vibrant innovation hub on the campus since beginning StarNav, which is where he also met U.S. Bank Business Access Advisor, and fellow Inland Empire native, Heli Castaneda.
'It has been a joy to support the business owners and students who participate in the programs at UCR,' said Castaneda.
As a native of the Inland Empire who is raising his children there, Castaneda shares Morales' desire to invest in his community.
'This is where I have the privilege of being able to be of service to local businesses and students,' Castaneda said. 'My role at U.S. Bank is all about bringing information, resources, and building bridges. My services are offered for free, and entrepreneurs don't have to be a U.S. Bank customer to work with me, and I really enjoy that part of my job! I'm here to help everyone.'
The relationship between U.S. Bank and UCR began with the work of Inland Southern California community affairs manager Rossina Gallegos, who saw the vision to empower Inland Empire residents, particularly underserved individuals, to launch high-growth, sustainably focused technology startups that create quality jobs. The program's first year concluded in March 2024 and received glowing participant feedback, with many calling it 'immensely valuable.' In addition to the funding, in 2023 and 2024 small business specialists from U.S. Bank participated in the selection of the SoCal OASIS Pitch Competition to help select the award winners of the program.
'At U.S. Bank, our whole mission is to invest our hearts and minds into powering human potential,' Gallegos said. 'We are happy to be able to support programs that serve brilliant students and innovative entrepreneurs who are equally invested in making our Inland Empire communities a better place to live and work.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
NextNav (NN) is Seeking Regulatory Play for its 5G Spectrum
Laughing Water Capital, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter of 2025, Class A interests in Laughing Water Capital returned approximately 13.1% net of all expenses. The SP500TR and R2000 returned 10.9% and 8.5%, respectively. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its second quarter 2025 investor letter, Laughing Water Capital highlighted stocks such as NextNav Inc. (NASDAQ:NN). NextNav Inc. (NASDAQ:NN) provides next-generation positioning, navigation, and timing (PNT) solutions. The one-month return of NextNav Inc. (NASDAQ:NN) was 2.25%, and its shares gained 88.51% of their value over the last 52 weeks. On July 23, 2025, NextNav Inc. (NASDAQ:NN) stock closed at $15.42 per share, with a market capitalization of $2.042 billion. Laughing Water Capital stated the following regarding NextNav Inc. (NASDAQ:NN) in its second quarter 2025 investor letter: "NextNav Inc. (NASDAQ:NN) – NextNav, which is our next-gen GPS and spectrum company, continues to march the ball forward in their quest to have the FCC greenlight their spectrum for 5G use. I continue to believe that the odds of NextNav succeeding are very favorable. This belief comes from the obvious, such as reading FCC filings where NextNav is specifically named, but also from more and more articles highlighting the vulnerabilities of the existing GPS system and the National Security needs of the United States. Additionally, it is hard to interpret the official FCC Twitter/X account re-tweeting articles written by NextNav's CEO as a bad sign, and perhaps most important is reading the tea leaves and digging up the scuttlebutt surrounding the various personalities involved behind the scenes. An aerial view of a bustling metropolis with internet towers in the distance. NextNav Inc. (NASDAQ:NN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 32 hedge fund portfolios held NextNav Inc. (NASDAQ:NN) at the end of the first quarter, which was 23 in the previous quarter. NextNav Inc.'s (NASDAQ:NN) first quarter revenue increased to $1.5 million from $1 million in Q1 2024. While we acknowledge the potential of NextNav Inc. (NASDAQ:NN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Wire
22 minutes ago
- Business Wire
ISG Names GTT a Leader for SASE and Managed SD-WAN in U.S. and U.K.
ARLINGTON, Va.--(BUSINESS WIRE)-- GTT Communications Inc., a leading networking and security as a service provider for multinational organizations, announced it has been named a Secure Service Access Edge (SASE) and Managed SD-WAN Leader in the United States and in the United Kingdom by the Information Services Group (ISG), a leading technology research and market intelligence advisory firm. 'Leaders,' as recognized by ISG, stand out for their comprehensive product and managed service offerings, strength in innovation and market competitiveness. GTT delivers powerful and advanced SASE and SSE solutions with vendor-agnostic, client-specific delivery supported by its Envision platform. Customers benefit from GTT's customized managed SD-WAN services and its global Tier 1 backbone. The 2025 ISG Provider Lens™ Network – Software-Defined Solutions and Services reports provide a detailed analysis of the markets for managed SD-WAN services, SD-networks transformation services, SASE and edge technologies and services, assessing over 150 U.S. providers and 40 U.K. providers. ISG offers strategic insights for technology and procurement leaders evaluating security and networking investments, including how providers support the shift to comprehensive SASE frameworks. The reports also assess managed SD-WAN offerings, with a focus on flexible solution management and modern contracts. In addition to the 'Leader' recognition in the U.S. and U.K. Quadrants for Managed SD-WAN and SASE, GTT has been named a ''Rising Star' in the SD-Networks Transformation Services category in both regions for its advisory, consulting and implementation services. 'Aligned with the shift towards Zero Trust, our research across the U.S. and U.K. shows rising demand for integrated security solutions that protect the entire enterprise network infrastructure,' said Dr. Kenn D. Walters, Lead Analyst, ISG. 'GTT delivers powerful and advanced SASE and SSE solutions with vendor-agnostic, client-specific delivery supported by its Envision platform. Customers benefit from GTT's customized managed SD-WAN services and its global Tier 1 backbone that ensures secure, high-performance connectivity from core to edge. GTT's leading advisory professionals further support a fully comprehensive range of customer requirements.' ISG highlights GTT's flexible, technology-agnostic SASE and SD-WAN solutions, powered by the GTT Envision platform that enables seamless network connection, orchestration, virtualization and automation. The firm notes that EnvisionDX, a digital gateway, delivers control for enhanced application performance and streamlined network policy management. ISG further highlights GTT's observability-driven governance, which helps enterprises leverage telemetry and AI-driven insights to identify optimization opportunities across legacy and modernized infrastructure. 'GTT is proud to be recognized by ISG for our ability to help CIOs standardize or diversify their architectures without sacrificing feature parity, visibility or policy control,' said Tom Major, Senior Vice President Product Management and Technology, GTT. 'With our global network reach and tightly integrated security, networking and cloud advisory services, we work with our customers to drive business success and deliver greater technology together.' Read the ISG reports to see the full analysis. About GTT GTT is a leading networking and security-as-a-service provider for multinational organizations, connecting people and machines to data and applications — anywhere in the world. We serve thousands of organizations, bringing together the right people, partners and technology to reduce the burden on IT teams and solve the most pressing networking and security challenges. Built on our top-ranked global Tier 1 network, the GTT Envision platform provides visibility, insights, orchestration and control, enabling customers with consumable solutions to achieve business missions and meet ongoing demand when, where and how needed. Our portfolio includes SASE, SD-WAN, security, internet, voice and other connectivity options, complemented by a suite of professional services and exceptional sales and support teams in local markets around the globe. We partner with our customers to deliver Greater Technology Together. Press releases can be downloaded from Follow us on LinkedIn, X, Facebook and YouTube.
Business Wire
22 minutes ago
- Business Wire
Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that its subsidiary, Pearsanta, Inc. (' Pearsanta'), has received an invitation to submit a full proposal for the Congressionally Directed Medical Research Program's (CDMRP) Ovarian Cancer Research Program ('OCRP') Pilot Award, funded through the U.S. Department of Defense (Funding Opportunity Number: HT942525OCRPPA) for its Mitomic® Ovarian Test ('MOT™'), a novel blood-based diagnostic for ovarian cancer. Pearsanta's Mitomic® technology is a platform that is designed to use mitochondrial DNA to identify biomarkers and to develop tests for early detection of cancer and other diseases. Pearsanta is currently conducting clinical validation of the first two tests that have been developed based on this technology for early detection of prostate cancer and endometriosis. MOT™ will potentially be another blood-based test to be added to the Company's product pipeline designed for earlier detection of ovarian cancer. Ovarian cancer currently has a poor prognosis due to the fact that it is typically detected in later stages. Early detection of ovarian cancer can potentially improve the outcomes for women who face this terrible disease. Pearsanta submitted a pre-proposal on June 10, 2025, which was favorably reviewed for its scientific merit, level of innovation, alignment with OCRP Areas of Interest, and potential impact. The full proposal, titled 'Mitochondrial DNA Deletions in Plasma as a Diagnostic Aid for Ovarian Cancer,' is currently under development and will be submitted by the September 11, 2025, deadline. The OCRP Pilot Award offers up to $350,000 over two years to support high-risk, high-reward research that could lead to critical discoveries and advance the field of ovarian cancer diagnostics and treatment. Pearsanta's proposed project aligns directly with the program's priority to 'identify and develop new strategies for screening, early-stage detection, accurate diagnosis, and prognosis.' 'Early detection is one of the greatest unmet needs in ovarian cancer care,' said Chris Mitton, President of Pearsanta. 'Our Mitomic® Ovarian Test has the potential to enable timely, more effective interventions, improve survival rates, and ultimately save lives. If successful, it could change the standard of care by offering a simple blood test that detects ovarian cancer at an earlier, more treatable stage—potentially improving survival and quality of life for women.' The study aims to further develop and validate the MOT™ at Pearsanta's Richmond, Virginia CLIA/CAP laboratory and monitoring facility in preparation for commercial launch as a laboratory-developed test (LDT). Plans include a prospective, multi-center clinical study to collect and analyze blood samples from women undergoing evaluation for suspected ovarian cancer. 'Pearsanta's continued progress is a powerful validation of our mission to accelerate promising health innovations with real-world impact,' said Amro Albanna, CEO of Aditxt. 'We believe the Mitomic® platform has the potential to transform how diseases are detected and managed. Supporting the development of the MOT™ reflects our broader strategy to Acquire high-potential innovations, Build them into clinically and commercially viable solutions, and Capitalize their value to drive scalable deployment globally. About Pearsanta Pearsanta is at the forefront of precision health, focusing on early cancer detection through advanced diagnostic technologies. Its proprietary Mitomic Technology Platform leverages the unique properties of mitochondrial DNA to detect cancer and other diseases with high accuracy via non-invasive, blood-based liquid, biopsy tests. Pearsanta's asset portfolio also includes a range of other innovative diagnostic technologies, all aimed at transforming early disease detection and monitoring, enabling more informed treatment decisions and ultimately improving patient outcomes. For more information, please visit About Aditxt, Inc. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health, and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the "A&R Merger Agreement"), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.0 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied, or that the transaction will ultimately close. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," "advancing", "aim," "are working to," "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to the potential success of Pearsanta's proposal for the U.S. Department of Defense Pilot Award; the ability of Pearsanta's Mitomic technology, including the MOT, to detect cancer or other diseases; Pearsanta's ability to commence in-human clinical trials on the proposed timeline, if at all; Aditxt's ability to successfully execute its mission to accelerate and monetize promising health innovations, and magnitude thereof; Aditxt's ability to complete the proposed initial public offering of Pearsanta on the proposed timeline, if at all; and Aditxt's ability to close the planned acquisition of Evofem, including to meet all closing conditions, and the timing thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company's SEC filings, including Aditxt's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 31, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law. For more information, please visit Follow Aditxt on:
